Study of NXP900 With Lorlatinib in ALK+ Lung Cancer

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a multi-center, open label, Phase 1b study of NXP900 in combination with lorlatinib in subjects with advanced, ALK-positive non-small cell lung cancer (NSCLC)
Epistemonikos ID: 1d608ec5c9ba7e3d4788f018602f34fcb6dfe2a6
First added on: Aug 26, 2026